Search

Displaying results 1221 - 1230 of 3388 in total
  1. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years.[A189207] Ubrogepant was approved by Health Canada on November 10, 2022. … [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.

    Categories: Calcitonin Gene-Related Peptide Receptor Antagonists, P-glycoprotein substrates
  2. Drug

    PH-797804

    go.drugbank.com/drugs/DB07941
    Investigational

    PH-797804 has been investigated for the treatment of Osteoarthritis.

  3. Drug

    Cholecalciferol

    go.drugbank.com/drugs/DB00169
    ApprovedInvestigationalNutraceutical

    Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight . Both the endogenous form of vitamin D (that results fro...

    Mixtures: Virt-Pn, Virt-PNCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Inhibitors
  4. Drug

    Sodium phosphate, monobasic, unspecified form

    go.drugbank.com/drugs/DB14503
    Approved

    Mixtures: Uta, Uta
  5. Drug

    PD-168393

    go.drugbank.com/drugs/DB07662
    Experimental

    PD-168393 is an epidermal growth factor receptor inhibitor.

  6. Drug

    Atazanavir

    go.drugbank.com/drugs/DB01072
    ApprovedInvestigational

    Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class.

    Categories: P-glycoprotein inducers, P-glycoprotein inhibitors
  7. Drug

    PD-169316

    go.drugbank.com/drugs/DB17040
    Experimental

    PD-169316 is a p38 MAP kinase inhibitor.[A253062]

  8. Drug

    PD-173952

    go.drugbank.com/drugs/DB17041
    Experimental

    PD-173952 is a potent Myt1 kinase inhibitor.[A253067]

  9. Drug

    Inotuzumab ozogamicin

    go.drugbank.com/drugs/DB05889
    ApprovedInvestigational

    Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide. The antibody por...

    Categories: P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index
  10. Drug

    PF-04447943

    go.drugbank.com/drugs/DB11953
    Investigational

    PF-04447943 has been investigated for the treatment of Alzheimer's Disease.